NCT05027997View on ClinicalTrials.gov

Exploratory Study of Dipraglurant (ADX48621) for the Treatment of Patients With Blepharospasm

PHASE2CompletedINTERVENTIONAL

Enrollment

15

Participants

Timeline

Start Date

October 6, 2021

Primary Completion Date

October 27, 2022

Study Completion Date

November 27, 2022

Conditions

BlepharospasmDystonia

Interventions

DRUG

Dipraglurant

Oral tablet

DRUG

Placebo

Oral matching placebo tablet

Trial Locations (1)

30329

Emory University, Atlanta

Sponsors

Lead Sponsor

Addex Pharma S.A.

All Listed Sponsors

lead

Addex Pharma S.A.

INDUSTRY

NCT05027997 - Exploratory Study of Dipraglurant (ADX48621) for the Treatment of Patients With Blepharospasm | Biotech Hunter | Biotech Hunter